KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (2018 - 2026)

Amneal Pharmaceuticals has reported Shares Outstanding over the past 8 years, most recently at $314.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.51% year-over-year to $314.6 million; the TTM value through Dec 2025 reached $314.6 million, up 1.51%, while the annual FY2025 figure was $314.6 million, 1.51% up from the prior year.
  • Shares Outstanding for Q4 2025 was $314.6 million at Amneal Pharmaceuticals, roughly flat from $314.3 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $314.6 million in Q4 2025 and troughed at $151.2 million in Q2 2022.
  • A 5-year average of $222.9 million and a median of $153.1 million in 2021 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: fell 0.45% in 2022 and later soared 101.53% in 2023.
  • Year by year, Shares Outstanding stood at $152.1 million in 2021, then changed by 0.0% to $152.1 million in 2022, then skyrocketed by 101.53% to $306.6 million in 2023, then grew by 1.08% to $309.9 million in 2024, then grew by 1.51% to $314.6 million in 2025.
  • Business Quant data shows Shares Outstanding for AMRX at $314.6 million in Q4 2025, $314.3 million in Q3 2025, and $314.0 million in Q2 2025.